Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00674752 · ClinicalTrials.gov registry record · Phase 3
A Polysomnographic Study Of Single-Dose Gabapentin In Transient Insomnia
A Phase 3 study of Transient Insomnia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 377
- Enrollment target
- 4
- Study locations
NCT00674752 is a Phase 3 study of Transient Insomnia that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 377 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT00674752, a Phase 3 study of Transient Insomnia, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 377 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to assess the effect of gabapentin on polysomnographic assessments in transient insomnia induced by a sleep phase advance.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Gabapentin
Study Locations (4)
Florida
- Pfizer Investigational Site - Miami
Georgia
- Pfizer Investigational Site - Atlanta
Kansas
- Pfizer Investigational Site - Overland Park
Ohio
- Pfizer Investigational Site - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 377 participants |
| Start Date | 2006-03 |
| Est. Completion | 2006-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00674752
The ClinicalTrials.gov registry entry for NCT00674752 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 377 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transient Insomnia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00674752 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Georgia, Kansas.
Frequently Asked Questions
What is clinical trial NCT00674752 about?
NCT00674752 is a clinical study titled "A Polysomnographic Study Of Single-Dose Gabapentin In Transient Insomnia". The purpose of this study is to assess the effect of gabapentin on polysomnographic assessments in transient insomnia induced by a sleep phase advance.
What is the current status of trial NCT00674752?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 377 participants. The study started on 2006-03. Estimated completion is 2006-08.
What conditions does trial NCT00674752 study?
This clinical trial studies the following conditions: Transient Insomnia.
What interventions are being tested in trial NCT00674752?
The interventions under investigation include: Placebo (DRUG), Gabapentin (DRUG).
Who is sponsoring clinical trial NCT00674752?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00674752 being conducted?
This trial has 4 study locations across Florida, Georgia, Kansas, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transient Insomnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.